Literature DB >> 28651219

A 20-Year multi-followup longitudinal study assessing whether antipsychotic medications contribute to work functioning in schizophrenia.

Martin Harrow1, Thomas H Jobe2, Robert N Faull2, Jie Yang3.   

Abstract

To assess the long-term effectiveness of antipsychotic medications in facilitating work functioning in patients with schizophrenia we conducted longitudinal multifollowup research on 139 initially psychotic patients. The 70 patients with schizophrenia and 69 initially psychotic mood disordered control patients were followed up 6 times over 20 years. We compared the influence on work functioning of patients with schizophrenia continuously prescribed antipsychotics with patients with schizophrenia not prescribed antipsychotics, using statistical controls for inter-subject differences. While antipsychotics reduce or eliminate flagrant psychosis for most patients with schizophrenia at acute hospitalizations, four years later and continually until the 20 year followups, patients with schizophrenia not prescribed antipsychotics had significantly better work functioning. The work performance of the patients who were continuously prescribed antipsychotics was at a low rate and did not improve over time. Multiple other factors also interfere with work functioning. The data suggest that some patients with schizophrenia not prescribed antipsychotics for prolonged periods can function relatively well. Multiple other factors are associated with poor post-hospital work performance. The longitudinal data raise questions about prolonged treatment of schizophrenia with antipsychotic medications.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Employment; Negative symptoms; Outcome; Psychosis; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28651219      PMCID: PMC5661946          DOI: 10.1016/j.psychres.2017.06.069

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  56 in total

1.  Statistical analysis of correlated data using generalized estimating equations: an orientation.

Authors:  James A Hanley; Abdissa Negassa; Michael D deB Edwardes; Janet E Forrester
Journal:  Am J Epidemiol       Date:  2003-02-15       Impact factor: 4.897

2.  Generalizability of the Individual Placement and Support (IPS) model of supported employment outside the US.

Authors:  Gary R Bond; Robert E Drake; Deborah R Becker
Journal:  World Psychiatry       Date:  2012-02       Impact factor: 49.548

Review 3.  World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.

Authors:  Rajiv Tandon; R H Belmaker; Wagner F Gattaz; Juan J Lopez-Ibor; Ahmed Okasha; Bruce Singh; Dan J Stein; Jean-Pierre Olie; W Wolfang Fleischhacker; Hans-Juergen Moeller
Journal:  Schizophr Res       Date:  2008-02-19       Impact factor: 4.939

4.  Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more.

Authors:  Patrick McGorry; Mario Alvarez-Jimenez; Eoin Killackey
Journal:  JAMA Psychiatry       Date:  2013-09       Impact factor: 21.596

5.  Mental health system funding of cognitive enhancement interventions for schizophrenia: summary and update of the New York Office of Mental Health expert panel and stakeholder meeting.

Authors:  Susan R McGurk; Kim T Mueser; Nancy H Covell; Keith D Cicerone; Robert E Drake; Steven M Silverstein; Alice Medialia; Robert Myers; Alan S Bellack; Morris D Bell; Susan M Essock
Journal:  Psychiatr Rehabil J       Date:  2013-09

Review 6.  Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?

Authors:  Martin Harrow; Thomas H Jobe
Journal:  Schizophr Bull       Date:  2013-03-19       Impact factor: 9.306

7.  Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study.

Authors:  S Silvestri; M V Seeman; J C Negrete; S Houle; C M Shammi; G J Remington; S Kapur; R B Zipursky; A A Wilson; B K Christensen; P Seeman
Journal:  Psychopharmacology (Berl)       Date:  2000-10       Impact factor: 4.530

8.  Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia.

Authors:  Tomotaka Suzuki; Nobuhisa Kanahara; Hiroshi Yamanaka; Masayuki Takase; Hiroshi Kimura; Hiroyuki Watanabe; Masaomi Iyo
Journal:  Psychiatry Res       Date:  2015-03-31       Impact factor: 3.222

9.  Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial.

Authors:  Lex Wunderink; Roeline M Nieboer; Durk Wiersma; Sjoerd Sytema; Fokko J Nienhuis
Journal:  JAMA Psychiatry       Date:  2013-09       Impact factor: 21.596

Review 10.  Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?

Authors:  Robin M Murray; Diego Quattrone; Sridhar Natesan; Jim van Os; Merete Nordentoft; Oliver Howes; Marta Di Forti; David Taylor
Journal:  Br J Psychiatry       Date:  2016-11       Impact factor: 9.319

View more
  10 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Long-term antipsychotic treatment of schizophrenia: does it help or hurt over a 20-year period?

Authors:  Martin Harrow; Thomas H Jobe
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

3.  Five Year Outcomes of Tapering Antipsychotic Drug Doses in a Community Mental Health Center.

Authors:  Sandra Steingard
Journal:  Community Ment Health J       Date:  2018-08-03

Review 4.  Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm.

Authors:  Chen-Chung Liu; Hiroyoshi Takeuchi
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

5.  A Real-World Observation of Antipsychotic Effects on Brain Volumes and Intrinsic Brain Activity in Schizophrenia.

Authors:  Yifan Chen; Fay Y Womer; Ruiqi Feng; Xizhe Zhang; Yanbo Zhang; Jia Duan; Miao Chang; Zhiyang Yin; Xiaowei Jiang; Shengnan Wei; Yange Wei; Yanqing Tang; Fei Wang
Journal:  Front Neurosci       Date:  2022-02-09       Impact factor: 4.677

6.  Identifying subgroups based on self-assessment of ability in patients with schizophrenia and its relationship with vocational outcomes.

Authors:  Hiroki Okada
Journal:  Hong Kong J Occup Ther       Date:  2022-02-17       Impact factor: 1.476

7.  Using Open Questions to Understand 650 People's Experiences With Antipsychotic Drugs.

Authors:  John Read; Ann Sacia
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

8.  Discontinuing Antipsychotic Medication After Remission from First-Episode Psychosis: A Survey of Psychiatrists' Attitudes in Taiwan.

Authors:  Ko Yen; Chen-Chung Liu; Yi-Ting Lin; Yi-Ling Chien; Ming H Hsieh; Chih-Min Liu; Tzung-Jeng Hwang; Wei-Hsiang Liao; Hai-Gwo Hwu
Journal:  Neuropsychiatr Dis Treat       Date:  2022-03-01       Impact factor: 2.570

9.  Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness.

Authors:  Petros Drosos; Erik Johnsen; Christoffer Andreas Bartz-Johannessen; Tor Ketil Larsen; Solveig Klæbo Reitan; Maria Rettenbacher; Rune Andreas Kroken
Journal:  World J Psychiatry       Date:  2022-03-19

10.  Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study.

Authors:  Jose M Rubio; Heidi Taipale; Antti Tanskanen; Christoph U Correll; John M Kane; Jari Tiihonen
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 7.348

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.